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Abstract
Background: Twist1 and Twist2 are highly homologous bHLH transcription factors that exhibit extensive highly overlapping
expression profiles during development. While both proteins have been shown to inhibit osteogenesis, only Twist1
haploinsufficiency is associated with the premature synostosis of cranial sutures in mice and humans. On the other hand,
biallelic Twist2 deficiency causes only a focal facial dermal dysplasia syndrome or additional cachexia and perinatal lethality
in certain mouse strains. It is unclear how these proteins cooperate to synergistically regulate bone formation.
Methods: Twist1 floxed mice (Twist1f/f) were bred with Twist2-Cre knock-in mice (Twist2Cre/+) to generate Twist1 and Twist2
haploinsufficient mice (Twist1f/+; Twist2Cre/+). X-radiography, micro-CT scans, alcian blue/alizarin red staining, trap staining,
BrdU labeling, immunohistochemistry, in situ hybridizations, real-time PCR and dual luciferase assay were employed to
investigate the overall skeletal defects and the bone-associated molecular and cellular changes of Twist1f/+;Twist2Cre/+ mice.
Results: Twist1 and Twist2 haploinsufficient mice did not present with premature ossification and craniosynostosis; instead
they displayed reduced bone formation, impaired proliferation and differentiation of osteoprogenitors. These mice
exhibited decreased expressions of Fgf2 and Fgfr1–4 in bone, resulting in a down-regulation of FGF signaling. Furthermore,
in vitro studies indicated that both Twist1 and Twist2 stimulated 4.9 kb Fgfr2 promoter activity in the presence of E12, a
Twist binding partner.
Conclusion: These data demonstrated that Twist1- and Twist2-haploinsufficiency caused reduced bone formation due to
compromised FGF signaling.
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Introduction
Mammalian Twist1 and Twist2 are two members of the Twist
subfamily of the basic-helix-loop-helix (bHLH) transcription
factors that have been highly conserved during evolution [1]. In
Drosophila, a single Twist gene, DTwist, is essential for embryonic
gastrulation and mesodermal formation [2,3]. Mouse Twist1 was
identified by its high homology with DTwist [4,5], while Twist2,
originally called ‘‘Dermo1’’, was discovered by a yeast-two-hybrid
screen using the ubiquitous bHLH protein E12 as bait [6]. The
expression patterns of Twist1 and Twist2 show an extensive
overlap during mouse embryonic development [6], and their
encoded proteins exhibit a high degree (up to 98%) of sequence
similarity [7]. Both proteins perform various functions by forming
either homodimers or heterodimers with bHLH E proteins (E12/
E47) that bind to DNA canonical regulatory sequences called ‘‘E-
boxes’’ (CANNTG) in the promoter region of target genes [8].
In humans, mutations in the TWIST1 gene are associated with
Saethre-Chotzen Syndrome (SCS), which is an autosomal
dominant disorder characterized by craniosynostosis, brachydac-
tyly, soft tissue syndactyly and facial dysmorphism [9]. The skeletal
phenotype of Twist1-heterozygous mouse consistently resembles
that of human SCS with premature fusion of the cranial suture
[9,10]. As mouse embryonic development progresses, the Twist1
expression declines in the developing bones of the skull [11]. In
addition, Twist1 overexpression was found to inhibit osteoblast
differentiation in vitro and in vivo [12,13,14]. Together, these
observations suggest that Twist1 negatively regulates osteoblast
differentiation and bone formation.
Various molecular mechanisms may be responsible for the
inhibitory role of Twist1 in osteoblast differentiation. Twist1 may
modulate FGF signaling, especially Fgfr2 expression in cranial
suture development [15,16,17] or it may directly bind to and
inhibit the transactivation function of Runx2, a master regulator of
osteogenesis [11]. In addition, Twist1 might indirectly regulate the
Runx2 expression through modulating FGFR2 expression as shown
in the ex vivo cultured primary osteoblasts isolated from human
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SCS patients [18]. Finally, it is possible that Twist1 inhibits
osteoblast apoptosis via the suppression of TNF-a expression [19].
Twist2 has been shown to have an inhibitory function similar to
that of Twist1 in bone formation [11]. While recessive TWIST2
mutations in humans and its inactivation in mice result in a focal
facial dermal dysplasia (FFDD) syndrome, there is no Twist2-
deficient skeletal phenotype [20]. The phenotypic difference
between the Twist1- and Twist2-deficient subjects is indeed
intriguing when viewed in the context of their significantly
overlapping expression patterns in vivo [6] and their similar
functions in bone formation [11]. Thus, it is largely unknown how
Twist1 and Twist2 synergistically regulate bone formation and
what molecular mechanism is involved.
In this study, we generated a compound Twist1- and Twist2-
haploinsufficient animal model, Twist1flox/+; Twist2Cre/+ mice, by
crossing Twist1 floxed mice with Twist2 Cre knock-in mice. Thus,
the compound Twist1flox/+; Twist2Cre/+ mice had one allele of
Twist2 replaced by the cre recombinase and one allele of Twist1
deleted specifically in tissues where the Twist2 gene was expressed.
To our surprise, we found that the Twist1flox/+; Twist2Cre/+ mice
exhibited reduced bone formation and impaired proliferation and
differentiation of osteoprogenitors. The skeletal abnormalities were
associated with reduced FGF signaling as a consequence of the
decreased expressions of Fgf2 and Fgfrs.
Materials and Methods
Ethical Approval
All animal protocols were approved by the Institutional Animal
Care and Use Committee (IACUC) at Texas A&M University
Baylor College of Dentistry. IACUC has specifically given ethical
approval for all the procedures in this study.
Generation of Twist1flox/+; Twist2Cre/+
Twist1 floxed mice (Twist1flox/flox) were maintained on a C57/
129 mixed genetic background [21] and Twist2 Cre Knock-in mice
(Twist2cre/+) were on a 129 genetic background [22]. The
Twist1flox/flox mice were bred with Twist2cre/+ mice to generate
compound Twist1flox/+; Twist2cre/+ mice. The Twist2Cre/+ mice
carry a Cre recombinase that replaces one allele of the Twist2 gene
[22]; therefore, the floxed Twist1 allele is deleted in the tissues
where the Twist2 gene is active. The Twist1 floxed mice and
Twist2Cre/+ mice were genotyped as described previously [21,22].
In this study, we analyzed the skeletal phenotype of 6–8 day-old
Twist1flox/+; Twist2Cre/+ mice and used age-matched Twist1flox/+;
Twist2+/+ as control mice (counting the day of birth as day 0).
Alcian blue/alizarin red staining of the skeleton
Alcian blue/alizarin red staining was performed to analyze the
overall skeletal and mineralization defects, as described previously
[23]. Briefly, 6-day-old Twist1flox/+; Twist2cre/+ mice and control
mice were sacrificed, skinned, eviscerated and fixed for three days
in 95% ethanol. They were then stained with alcian blue for
cartilage and alizarin red for bone visualization.
Plain X-ray radiography and high-resolution
microcomputed tomography (m-CT)
The femurs and tibiae from 6-day-old Twist1flox/+; Twist2cre/+
mice and control mice were dissected free of the skeletal muscles
and fixed in 70% ethanol. For plain X-ray radiography, the
femurs were analyzed with a Faxitron MX-20 specimen radiog-
raphy system (Faxitron X-ray Corp., Buffalo Grove, IL) as
described previously [24]. For the high-resolution m-CT analyses,
the tibiae were scanned at 3.5-mm resolution using a m-CT35
imaging system (Scanco Medical, Basserdorf, Switzerland), as
previously described [24]. The trabecular bone was analyzed at a
threshold of 160 in 20 sections underneath the growth plate.
Histology, immunohistochemistry and in situ
hybridization
For histologic analysis, the bone specimens from 6-day-old mice
were fixed in freshly prepared 4% paraformaldehyde, decalcified
in 10% EDTA with 0.5% paraformaldehyde, and embedded in
paraffin using standard procedures [25]. Serial 7-mm sections were
cut and mounted on silane-coated slides. The sections were then
used for Hematoxylin and Eosin (H&E) staining, Tatrate-resistant
alkaline phosphatase (TRAP) staining, immunohistochemistry or
in situ hybridization, as described previously [24,25].
The following antibodies were used for the immunohistochem-
ical analyses: anti-Osterix (Santa Cruz Biotechnology, Dallas, TX,
USA; 1:400), rabbit anti-biglycan antibody ‘‘LF-159’’ (a gift from
Dr. Larry Fisher, National Institutes of Health, Bethesda, MD;
1:1000), anti-Fgfr2 polyclonal antibody (Abcam, Cambridge, MA,
USA; 1:5000), and anti-phospho-p44/42 MAPK (Erk1/2) anti-
body (Cell Signaling Technology, Danvers, MA, USA; 1:100). All
the immunohistochemical experiments were performed with a 3,
3-diaminobenzidine kit (Vector Laboratories, Burlingame, CA)
according to the manufacturer’s instructions.
For the in situ hybridization, the RNA probes for dentin matrix
protein (Dmp1), osteocalcin (Ocn) and alkaline phosphatase (Alp)
were labeled with digoxigenin (DIG) using a RNA Labeling Kit
(Roche, Indianapolis, IN, USA) according to the manufacturer’s
instructions. DIG-labeled RNA probes were detected by an
enzyme-linked immunoassay with a specific anti-DIG-alkaline
phosphatase antibody conjugate (Roche, Indianapolis, IN) and a
Table 1. Primers used for real-time PCR.
Gene Forward primer (59-39) Reverse primer (59-39)
Fgf2 agcggctctactgcaagaac gccgtccatcttccttcata
Fgfr1 ttcagtggctgaagcacatc gcagagtgatgggagagtcc
Fgfr2 gtgcttggcgggtaattcta gatgactgtcaccaccatgc
Fgfr3 ccaccttcaagcagttggtag gggtgaacaccgagtcatct
Fgfr4 aagtcatccgtggccactac cgagaggcaggtctagattca
Erm gatgatgcctgaaagccagt gggaccccatgttcatacag
Pea3 cctatgactcccccagacaa cctccctgaggagatgtgaa
doi:10.1371/journal.pone.0099331.t001
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Figure 1. Reduced bone formation in Twist1flox/+; Twist2Cre/+ mice. (A) Skeletons of 6-day-old control (left) and Twist1flox/+; Twist2Cre/+ (right)
mice stained with alcian blue (cartilage) and alizarin red (bone). The skeleton of the Twist1flox/+; Twist2Cre/+ mouse is remarkably smaller. (B) Alcian
blue- and alizarin red-stained skull from 6-day-old Twist1flox/+; Twist2Cre/+ mice (right) showed delayed fusion of interfrontal suture and open posterior
fontanel (arrows), compared with the control mice (left). (C) Alcian blue- and alizarin red-stained hind foot of 6-day-old control (left) and Twist1flox/+;
Twist2Cre/+ (right) mice. Note the delayed ossification in metatarsals (mt) and phalanges (pl), and an additional toe (arrow) originating from the same
(or duplicated) metatarsal as the hallux in Twist1flox/+; Twist2Cre/+ mice. (D) Plain X-radiography of the tibiae from 6-day-old control (left) and Twist1flox/+;
Twist2Cre/+ mice (right). The Twist1flox/+; Twist2Cre/+ mice had shorter tibiae and reduced radiopacity, compared to the control mice. (E)
Representative three-dimensional m-CT images of tibiae from 6-day-old control (left) and Twist1flox/+; Twist2Cre/+ (right) mice. The Twist1flox/+;
Twist2Cre/+ mice showed reduced trabecular (arrowheads) and cortical bones (arrows). (F–H) Quantitative m-CT data showing that the 6-day-old
Twist1flox/+; Twist2Cre/+ mice had a significant decrease in the ratio of bone volume (BV)/total volume (TV) (F) and in apparent bone density
(G), compared to the control mice (n = 6, P,0.001). The Twist1flox/+; Twist2Cre/+ mice also presented reduced material density although no
statistically significant difference was observed (H).
doi:10.1371/journal.pone.0099331.g001
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VECTOR NBT/BCIP alkaline phosphatase substrate (Vector
Laboratories, Burlingame, CA), which produced a blue color
indicating positive signals. Methyl green was used for counter-
staining.
Cell proliferation assay
Six-day-old Twist1flox/+; Twist2cre/+ mice and control mice were
intraperitoneally injected with 5-bromo-29-deoxyuridine (BrdU)
(10 mg/100 g body weight) at 24 hours and then two hours before
sacrifice. The long bones were collected and processed for paraffin
sectioning as described above. The incorporated BrdU was
detected with a BrdU staining kit (Invitrogen, Camarillo, CA,
USA) according to the manufacturer’s instructions. The BrdU-
positive nuclei and total nuclei were counted in the metaphysis
region (trabecular bone) as well as in the midshaft (cortical bone).
The data represented the percentage of BrdU-positive nuclei from
four individual animals each group.
Quantitative Real-time PCR
Total RNA was extracted using Trizol (Invitrogen, Camarillo,
CA, USA) from the long bones of 8-day-old Twist1/2 dHet mice
and control mice and reverse-transcribed into cDNA with a
Reverse Transcription Kit (QIAGEN, Germantown, MD, USA).
Quantitative real-time PCR (qPCR) was performed using a Go
Tag qPCR Master Mix System (Promega, Madison, WI, USA).
Mouse 18S rRNA primers (PPM57735E-200, QIAGEN, German-
town, MD, USA) were used for normalization. The primers for
Alp, Ocn, bone sialoprotein (Bsp), osterix (Osx), Dmp1 and Runx2
were reported elsewhere [26,27]. The primers for Fgf2, Fgfr1,
Fgfr2, Fgfr3, Fgfr4, Erm (Etv5) and Pea3 (Etv4) are listed in Table 1.
The primers for Fgfr2 were specifically designed to amplify the
mesenchymal isoform of Fgfr2 (Fgfr2-IIIc). All experiments were
performed in triplicate on three animals. The data were analyzed
using the 22DDCT method as described previously [28].
Cell culture, constructs and promoter luciferase assay
The C3H10T1/2 mesenchymal cells and MC3T3-E1 preosteo-
blast cells were cultured as described previously [29]. A 4.9 kb-
Fgfr2 promoter luciferase construct and expression constructs for
Twist1 and E12 have been reported elsewhere [30]. An expression
construct for Twist2 was generated by cloning Twist2 cDNA into
the BamHI and EcoRI sites of pcDNA3 vector (Invitrogen). The
Figure 2. Histological examination of Twist1flox/+; Twist2Cre/+ mice. (A–B) Femur sections of 6-day-old control and Twist1flox/+; Twist2Cre/+ mice
were stained with H&E. The Twist1flox/+; Twist2Cre/+ mice displayed reduced metaphyseal trabecular bone (A, red arrows) and a decreased thickness of
the periosteum (B, blue arrows) and cortical bone (B, red arrows). (C) TRAP staining of femur sections of 6-day-old control and Twist1flox/+; Twist2Cre/+
mice. Note that the osteoclasts (red arrows) appeared to be similar in size and distribution in the control and Twist1flox/+; Twist2Cre/+ mice. The
osteoclast densities were 0.5560.06/0.01 mm2 in the controls (n= 5) and 0.6060.02/0.01 mm2 in the Twist1flox/+; Twist2Cre/+ mice (n=5, P.0.05). (D–F)
In situ hybridization analyses (signal in blue) of the transcripts of Alp (D), Ocn (E) and Dmp1 (F) in the femurs of one-week-old control and Twist1flox/+;
Twist2Cre/+ mice. (G, H) Immunohistochemical analyses (signal in brown) of the osterix (G) and biglycan (H) protein levels in the femurs of the 6-day-
old control and Twist1flox/+; Twist2Cre/+ mice. Scale bar = 100 mm.
doi:10.1371/journal.pone.0099331.g002
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promoter luciferase assay was performed as described previously
[24,30]. Briefly, C3H10T1/2 cells and MC3T3-E1 cells were
plated in 24-well plates at a density of 36104 cells per well. Then
the cells were transiently transfected with 0.1 mg of 4.9 kb-Fgfr2
promoter luciferase construct, together with 0.4 mg of various
constructs expressing Twist1, Twist2 or E12 using FuGENE 6
Transfection Reagent (Roche, Indianapolis, IN, USA). The total
amounts of transfected DNA were balanced by the addition of an
empty vector (pcDNA3). A Renilla luciferase expression construct
was co-transfected as an internal control to monitor the
transfection efficiency. Forty-eight hours later, the transfected
cells were analyzed using a dual luciferase reporter assay system
(Promega, Madison, WI, USA). The luciferase activities were
normalized by the control. All experiments were carried out in
triplicate and repeated three times.
Statistical analysis
The statistical analyses were performed with a one-way
ANOVA for a multiple group comparison and the Student’s t-
test for a two-group comparison. If significant differences were
found with the one-way ANOVA, the Student’s t-test was used to
determine which groups were significantly different from the
others. The quantified results were expressed as mean 6 standard
deviation (SD). P,0.05 was considered to be statistically
significant.
Results
Generation of Twist1- and Twist2-haploinsufficient mice
Twist1flox/+; Twist2Cre/+ mice were generated by breeding Twist1
floxed mice (Twist1flox/flox) with Twist2 Cre Knock-in mice
(Twist2cre/+), in which one allele of Twist2 was replaced by the
Cre recombinase. Twist2-Cre is active in the condensed mesen-
chyme that will later produce the chondrocytes and osteoblasts
[22]; therefore, in the compound Twist1flox/+; Twist2Cre/+ mice, the
floxed Twist1 allele is deleted in the osteoblasts and their
precursors. Consequently, both Twist1 and Twist2 were haploin-
sufficient in the osteoblast lineage of the Twist1flox/+; Twist2Cre/+
mice. Real-time PCR confirmed that the mRNA levels of both
Twist1 and Twist2 were about three folds less in the Twist1flox/+;
Twist2Cre/+ mice than in the control mice (Figure S1). Although the
floxed Twist1 allele was conditionally deleted, the compound
Twist1flox/+; Twist2Cre/+ mice had a phenotype similar to that of the
mice completely heterozygous for both the Twist1 and Twist2
genes [31]. Most of them died within two weeks after birth but a
few of them survived to adulthood and were fertile.
Reduced bone formation in Twist1flox/+; Twist2Cre/+ mice
We first examined the overall skeletal structures of Twist1flox/+;
Twist2Cre/+ mice in Figure 1. The alcian blue/alizarin red staining
showed that Twist1flox/+; Twist2Cre/+ mice had a much smaller
skeleton with delayed fusion of the interfrontal suture, open
posterior fontanelles and delayed ossification in the metatarsals
and phalanges (Figs. 1A–C). In addition, the Twist1flox/+; Twist2Cre/+
mice developed an extra toe close to the hallux (Fig. 1C), the
hallmark of Twist1 heterozygous mice [32]. Plain X-radiography
showed that the Twist1flox/+; Twist2Cre/+ mice had reduced
radiopacity in the tibiae compared to the control mice (Fig. 1D).
Micro-CT images further confirmed that the Twist1flox/+;
Twist2Cre/+ mice had reduced trabecular bone and decreased
cortical bone thickness (Fig. 1E). The quantitative analyses
revealed a significant decrease in trabecular bone volume versus
total volume (BV/TV) and in apparent bone density in the
Twist1flox/+; Twist2Cre/+ mice (Figs. 1F–G). The material density
was also slightly reduced in the Twist1flox/+; Twist2Cre/+ mice
although the difference in this parameter was not statistically
significant compared to the control mice (Fig. 1H). These data
demonstrated that bone formation was inhibited in the
Twist1flox/+; Twist2Cre/+ mice.
Defects in osteoblast differentiation in Twist1flox/+;
Twist2Cre/+ mice
We carried out a series of histological and molecular analyses to
determine whether there were any abnormalities in osteoclast
numbers and/or osteoblast differentiation. First, H&E staining
confirmed that the Twist1flox/+; Twist2Cre/+ mice formed less
trabecular bone and thinner periosteum and cortical bone
(Figs. 2A–B). Second, TRAP staining showed that the distribution
and size of the osteoclasts in the Twist1flox/+; Twist2Cre/+ mice were
similar to those of the control mice (Fig. 2C). Although the
osteoclast density was slightly increased in the Twist1flox/+;
Twist2Cre/+ mice, no significant difference was observed between
two groups. Third, we examined the expression levels of the
osteoblast differentiation markers by in situ hybridization, immu-
nohistochemistry and real-time PCR. These methods revealed that
the levels of the osteoblast differentiation markers Alp (Figs. 2D
and 3), Ocn (Figs. 2E and 3), biglycan (Fig. 2H) and Bsp (Fig. 3)
Figure 3. Quantitative real-time PCR analyses of osteoblast differentiation markers. Real-time PCR was performed with total RNA isolated
from the long bones of the one-week-old control and Twist1flox/+; Twist2Cre/+ mice. The expressions of key transcription factors associated with
osteoblast differentiation (Runx2 and osterix), osteoblast markers (Alp, Ocn and Bsp) and osteocyte marker (Dmp1) were reduced in Twist1flox/+;
Twist2Cre/+ mice. The mRNA levels in the control mice were set as one, and the mRNA levels of Twist1flox/+; Twist2Cre/+ mice were expressed as folds of
those in the control mice. The data represented three analyses (n= 3) for each group.
doi:10.1371/journal.pone.0099331.g003
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were sharply reduced in the Twist1flox/+; Twist2Cre/+ mice
compared to the control mice. In addition, the osteocyte marker
Dmp1 was also dramatically decreased (Fig. 2F and 3). Further-
more, the expression levels of Runx2 and Osx, two key
transcription factors essential for osteoblast differentiation and
bone formation, were remarkably reduced in the Twist1flox/+;
Twist2Cre/+ mice, compared to the control mice (Figs. 2G and 3).
Taken together, these findings supported the hypothesis that the
reduced bone formation resulted from defects in osteoblast
differentiation rather than abnormal osteoclast activities.
Reduced cell proliferation in Twist1flox/+; Twist2Cre/+ mice
Since the Twist1flox/+; Twist2Cre/+ mice had a reduced periosteal
layer compared to the control mice (Fig. 2B), we performed BrdU
labeling to determine whether the proliferation of osteoblasts and
their progenitors was affected. We noticed that the BrdU-positive
cells in the area of the metaphysis (Figs. 4A), as well as in the mid
diaphyseal periosteum and cortical bone (Fig. 4D), were signifi-
cantly reduced in the Twist1flox/+; Twist2Cre/+ mice. However, no
difference in the osteoblast apoptosis was observed (Figure S2).
These findings suggested that the reduced cell proliferation might
Figure 4. Cell proliferation was reduced in the Twist1flox/+; Twist2Cre/+ mice. (A–B) BrdU immunohistochemical staining of the femur sections
of 7-day-old control and Twist1flox/+; Twist2Cre/+ mice. The BrdU-positive cells (signal in brown) were counted in a 100-mm zone of the metaphysis,
demarcated by the chondro-osseous junction and the marked line (A), and in the femoral diaphysis (B). The osteoblast/osteoprogenitor proliferation
was reduced in both the metaphysis (C) and diaphysis (D) in the Twist1flox/+; Twist2Cre/+ mice, compared to the control mice (n= 4, *P,0.05). The data
were expressed as the percentage of BrdU-positive nuclei versus total nuclei. Scale bars: 100 mm.
doi:10.1371/journal.pone.0099331.g004
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also contribute to the reduced bone formation in the Twist1flox/+;
Twist2Cre/+ mice.
Reduced FGF signaling in Twist1flox/+; Twist2Cre/+ mice
A variety of studies have indicated interactions between Twist1
and FGF signaling although the outcome of such interactions
appears to be context dependent [15,17,18,33]. We analyzed the
components of the FGF signaling pathway in the Twist1flox/+;
Twist2Cre/+ mice. Quantitative real-time PCR revealed a substan-
tial decrease in the transcript levels of Fgf2 and Fgfrs1, 2, 3 and 4 in
the Twist1flox/+; Twist2Cre/+ mice (Fig. 5A). Immunohistochemistry
further confirmed that the Fgfr2 protein was markedly reduced in
the long bones of the Twist1flox/+; Twist2Cre/+ mice (Fig. 5B). FGF
signaling triggered the MAP kinase cascade, resulting in the
phosphorylation and activation of p44/42 (Erk1/2) and the
expression of two effector molecules, Erm and Pea3 [34].
Consistent with the reduced Fgf2 and Fgfr expression, the
immunohistochemistry revealed that the levels of phospho-Erk1/
2 were considerably lower in Twist1flox/+; Twist2Cre/+ mice than in
the control mice (Fig. 5C). Accordingly, quantitative real-time
Figure 5. Reduced FGF signaling in Twist1flox/+; Twist2Cre/+ mice. (A) Quantitative real-time PCR was performed to analyze the mRNA levels of
Fgf2, Fgfr1, Fgfr2, Fgfr3 and Fgfr4, as well as two effector molecules, Erm and Pea3, using total RNA isolated from the long bones of 8-day-old control
and Twist1flox/+; Twist2Cre/+ mice. The mRNA levels in the control mice were set as one, and the mRNA levels of Twist1flox/+; Twist2Cre/+ mice were
expressed as folds of those in the control mice. The data represented three analyses (n=3) for each group. (B) Immunohistochemistry showed that
the level of the Fgfr2 protein (signal in brown) was reduced in the femurs of the Twist1flox/+; Twist2Cre/+ mice (right), compared to the control mice
(left). (C) Immunohistochemistry showed that there was less phospho-Erk1/2 (signal in brown) than in the femurs of Twist1flox/+; Twist2Cre/+ mice,
compared to the control mice. Scale bars: 100 mm.
doi:10.1371/journal.pone.0099331.g005
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PCR demonstrated that the levels of Erm and Pea3 transcripts were
significantly downregulated (Fig. 5A). These data demonstrated
that FGF signaling was reduced in the Twist1flox/+; Twist2Cre/+
mice, suggesting that Twist1 and Twist2 might upregulate the
expressions of Fgf2 and Fgfrs.
Twist1 and Twist2 stimulated Fgfr2 promoter activity
As described above, Fgfr2 was significantly downregulated at
both the mRNA and protein levels in the Twist1flox/+; Twist2Cre/+
mice. The skeletal phenotype of Twist1flox/+; Twist2Cre/+ mice
partially resembles that of the Fgfr2 conditional knock-out mice
[22]. Therefore, we examined whether Twist1 and Twist2 could
upregulate the Fgfr2 promoter activity in vitro. Our promoter
luciferase reporter assay revealed that Twist1 or Twist2 alone was
unable to significantly stimulate a 4.9 kb Fgfr2 promoter fragment.
However, they strongly enhanced the stimulatory activity of E12, a
ubiquitously expressed Twist binding partner, in both the
C3H10T1/2 mesenchymal cells and MC3T3-E1 pre-osteoblast
cells (Fig. 6). This in vitro evidence implied that Twist1 and Twist2,
together with E12, could regulate the Fgfr2 expression.
Discussion
Twist1 and Twist2 are two highly conserved members of the
Twist subfamily of bHLH transcription factors. In this study, we
generated Twist1- and Twist2-haploinsufficient mice (Twist1flox/+;
Twist2Cre/+), and found that these mice displayed delayed closure
of the cranial sutures. Furthermore, we found that the Twist1flox/+;
Twist2Cre/+ mice presented with reduced bone formation and
impaired osteoprogenitor proliferation and osteoblast differentia-
tion as well as compromised FGF signaling.
Previous studies have demonstrated that the cranial sutures of
the Twist1 heterozygous mice prematurely fuse [10,11,32]. To
confirm this finding, we crossed the Twist1-floxed mice (Twist1flox/flox)
with Sox2-Cre transgenic mice expressing a Cre recombinase
ubiquitously in the epiblast cells at embryonic day 6.5 and
generated conditional Twist1-haploinsufficient mice (Twist1flox/+;
Sox2-Cre) (Figure S3). We found that the Twist1flox/+; Sox2-Cre
mice developed craniosynostosis - a phenotype that is similar to
the Twist1 heterozygous mice [11,32], characterized by much
narrower sagittal and interfrontal sutures and had additional toe
originating from a duplicated metatarsal as demonstrated by
alcian blue and alizarin red staining (Figure S3A–D). The plain
X-radiography and histological examination did not reveal
apparent difference in the radiopacity of the long bones, in the
metaphyseal trabecular bones or in the diaphyseal cortical bones
between Twist1flox/+; Sox2-Cre and control mice (Figure S3E–G).
In contrast, although the Twist2 heterozygous mice are viable
and fertile with no apparent phenotype [20,31], the Twist1flox/+;
Twist2Cre/+ mice showed reduced growth of both cranial and
long bones as well as delayed closure of the cranial sutures.
Therefore, the Twist1flox/+; Twist2Cre/+ mice displayed a skeletal
phenotype that is opposite to that of Twist1 heterozygous mice.
Our current studies and the studies from other labs have
demonstrated that Twist1 and Twist2 share similar in vitro and in
vivo functions [11]. Therefore, the phenotypic difference between
single Twist1/2-heterozygous mice and Twist1flox/+; Twist2Cre/+
mice might be due to the overlapping expression patterns of Twist1
and Twist2 during mouse embryonic development [6]. Both Twist1
and Twist2 are highly expressed in the condensed mesenchyme
that later gives rise to osteoblasts and chondrocytes [6,11,22].
Thus, the outcomes of the loss of Twist1 and/or Twist2 really
depend on the relative expression of both genes in a specific tissue.
Accumulating evidence supports the notion that Twist1 might
control cranial suture development through modulating FGF
signaling. It was found that the mutations in FGF receptors
FGFR1, FGFR2, and FGFR3 in humans are associated with
craniosynostosis, a characteristic phenotype of the Saethre-
Chotzen Syndrome caused by dominant loss-of-function TWIST1
mutations [35]. In addition, the primary cranial osteoblasts
isolated from SCS patients with Twist1 mutations show reduced
FGFR2 transcript levels, which can be restored by overexpression
of TWIST1 [18]. Twist1 haploinsufficiency in mice also results in
an altered Fgfr2 expression pattern in the cranial sutures [17]. It
has been proposed that Twist1 haploinsufficiency favors the
formation of Twist1 homodimers in the osteogenic front of cranial
Figure 6. Effects of Twist1, Twist2 and E12 on the activity of a 4.9 kb Fgfr2 promoter fragment. C3H10T1/2 (A) and MC3T3-E1 cells (B)
were transiently co-transfected with a 4.9 kb Fgfr2 promoter luciferase construct and the indicated expression constructs, along with a pRL-TK
construct as an internal control. The luciferase activities were determined by a dual luciferase assay system, and the promoter activities were
expressed as luciferase activities relative to that of the control. The values represented mean 6 SD. n = 3 for each group. ‘‘a’’ indicates significant
difference from the control (p,0.05); ‘‘b’’ denotes a significant difference from all other groups (p,0.05).
doi:10.1371/journal.pone.0099331.g006
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sutures, which results in the upregulation of Fgfr2 expression and
leads to craniosynostosis [16]. Taken together, the data from these
human and mouse studies suggest that Twist1 might regulate FGF
signaling, particularly the Fgfr2 expression, in a context-dependent
manner.
Our current studies provide further support that Twist1 and
Twist2 regulate FGF signaling in bone formation. We found that
Twist1flox/+; Twist2Cre/+ mice had reduced FGF signaling in bone as
a result of decreased expression of not only Fgfr2 but also Fgfr1,
Fgfr3, Fgfr4 and even Fgf2. FGF signaling plays essential roles
throughout osteogenesis, including the commitment of mesenchy-
mal cells to osteoprogenitors, the proliferation and differentiation
of osteoprogenitors to osteoblasts, and osteoblast apoptosis [22,36].
Indeed, the Twist1flox/+; Twist2Cre/+ mice displayed reduced
proliferation of osteoprogenitor cells and defective osteoblast
differentiation. Some of the skeletal abnormalities even resemble
those of Fgfr2 conditional knockout mice [22]. Consistent with the
in vivo results, our in vitro promoter luciferase assays further
supported the role of Twist1 and Twist2 in the upregulation of
Fgfr2 promoter activity when E12 was present. However, it
remains to be determined why only Twist/E12 heterodimers,
instead of Twist homodimers, stimulate Fgfr2 promoter activity.
In summary, our current study suggested that Twist1 and
Twist2 may synergistically enhance the proliferation and differ-
entiation of osteoprogenitors via the upregulation of FGF signaling
during skeletal development. However, further studies are
necessary to determine whether these two genes perform identical
functions and could completely replace each other in vivo.
Research is also needed to advance our understanding of how
the expression levels of Twist1 and Twist2 are temporally and
spatially regulated during development and how fine-tuning
achieves the optimal Twist protein level needed for normal
skeletal development. Such knowledge is essential for the
development of future therapies aimed at correcting the effects
of Twist deficiency in humans.
Supporting Information
Figure S1 The mRNA levels of Twist1 and Twist2 in the
long bones of Twist1flox/+; Twist2Cre/+ mice. Real-time
PCR was performed with total RNA isolated from the long bones
of the 8-day-old control and Twist1flox/+; Twist2Cre/+ mice. The
primers used for Twist1 were sense 59- CAGCGGGTCATGGC-
TAAC-39 and antisense 59- GCAGGACCTGGTACAGGAAG-
39, and for Twist2 sense 59- AGCAAGAAATCGAGCGAAGA-39
and antisense 59- CAGCTTGAGCGTCTGGATCT-39. The
mRNA levels of Twist1 and Twist2 were about three folds less in
the Twist1flox/+; Twist2Cre/+ mice than in the control mice. The data
represented three analyses (n=3) for each group.
(TIF)
Figure S2 Osteoblast apoptosis in the Twist1flox/+;
Twist2Cre/+ mice. TUNEL assay was used to analyze the
osteoblast apoptosis in the long bones of 6-day-old Twist1flox/+;
Twist2Cre/+ mice and control mice. Three serial sections from each
of four individual Twist1flox/+; Twist2Cre/+ mice and control
littermates were counted. No significant difference in osteoblast
apoptosis was found between the two groups of mice.
(TIF)
Figure S3 Skeletal abnormalities of Twist1flox/+; Sox2-
Cremice. (A) The skeletons of 7-day-old Twist1flox/+ (control) and
Twist1flox/+; Sox2-Cre mice were stained with alcian blue and
alizarin red. (B–C) Alcian blue and alizarin red stained skulls,
femurs and tibiae, and hind feet from 7-day-old control mice and
Twist1flox/+; Sox2-Cre mice; The Twist1flox/+; Sox2-Cre mice showed
much narrower sagittal and interfrontal sutures (arrows; B) and
had additional toe (arrow) originating from a duplicated metatarsal
(MT; D), but the femurs and tibiae showed no apparent difference
between two groups (C). (E) Plain X-radiography of the hind limbs
from 7-day-old control and Twist1flox/+; Sox2-Cre mice. No
apparent difference was noted between the two groups of mice.
(F and G) Histological examination of Twist1flox/+; Sox2-Cre mice.
Tibia sections of 7-day-old control and Twist1flox/+; Sox2-Cre mice
were stained with H&E. No apparent difference was observed in
the metaphyseal trabecular bone (F) or in the diaphyseal cortical
bone (G) between these two groups.
(TIF)
Materials and Methods S1 Generation of Twist1flox/+;
Sox2-Cre mice.
(DOCX)
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